-
Something wrong with this record ?
Tick Salivary Compounds for Targeted Immunomodulatory Therapy
H. Aounallah, C. Bensaoud, Y. M'ghirbi, F. Faria, JI. Chmelar, M. Kotsyfakis
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- MeSH
- Autoimmune Diseases immunology therapy MeSH
- Immunomodulation immunology MeSH
- Ticks immunology MeSH
- Humans MeSH
- Immune System Diseases immunology therapy MeSH
- Arthropod Proteins immunology MeSH
- Saliva immunology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Immunodeficiency disorders and autoimmune diseases are common, but a lack of effective targeted drugs and the side-effects of existing drugs have stimulated interest in finding therapeutic alternatives. Naturally derived substances are a recognized source of novel drugs, and tick saliva is increasingly recognized as a rich source of bioactive molecules with specific functions. Ticks use their saliva to overcome the innate and adaptive host immune systems. Their saliva is a rich cocktail of molecules including proteins, peptides, lipid derivatives, and recently discovered non-coding RNAs that inhibit or modulate vertebrate immune reactions. A number of tick saliva and/or salivary gland molecules have been characterized and shown to be promising candidates for drug development for vertebrate immune diseases. However, further validation of these molecules at the molecular, cellular, and organism levels is now required to progress lead candidates to clinical testing. In this paper, we review the data on the immuno-pharmacological aspects of tick salivary compounds characterized in vitro and/or in vivo and present recent findings on non-coding RNAs that might be exploitable as immunomodulatory therapies.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020108
- 003
- CZ-PrNML
- 005
- 20210830101725.0
- 007
- ta
- 008
- 210728s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fimmu.2020.583845 $2 doi
- 035 __
- $a (PubMed)33072132
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Aounallah, Hajer $u Institut Pasteur de Tunis, LR19IPTX, Service d'Entomologie Médicale, Université de Tunis El Manar, Tunis, Tunisia $u Innovation and Development Laboratory, Innovation and Development Center, Instituto Butantan, São Paulo, Brazil
- 245 10
- $a Tick Salivary Compounds for Targeted Immunomodulatory Therapy / $c H. Aounallah, C. Bensaoud, Y. M'ghirbi, F. Faria, JI. Chmelar, M. Kotsyfakis
- 520 9_
- $a Immunodeficiency disorders and autoimmune diseases are common, but a lack of effective targeted drugs and the side-effects of existing drugs have stimulated interest in finding therapeutic alternatives. Naturally derived substances are a recognized source of novel drugs, and tick saliva is increasingly recognized as a rich source of bioactive molecules with specific functions. Ticks use their saliva to overcome the innate and adaptive host immune systems. Their saliva is a rich cocktail of molecules including proteins, peptides, lipid derivatives, and recently discovered non-coding RNAs that inhibit or modulate vertebrate immune reactions. A number of tick saliva and/or salivary gland molecules have been characterized and shown to be promising candidates for drug development for vertebrate immune diseases. However, further validation of these molecules at the molecular, cellular, and organism levels is now required to progress lead candidates to clinical testing. In this paper, we review the data on the immuno-pharmacological aspects of tick salivary compounds characterized in vitro and/or in vivo and present recent findings on non-coding RNAs that might be exploitable as immunomodulatory therapies.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a proteiny členovců $x imunologie $7 D060829
- 650 _2
- $a autoimunitní nemoci $x imunologie $x terapie $7 D001327
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nemoci imunitního systému $x imunologie $x terapie $7 D007154
- 650 _2
- $a imunomodulace $x imunologie $7 D056747
- 650 _2
- $a sliny $x imunologie $7 D012463
- 650 _2
- $a klíšťata $x imunologie $7 D013987
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bensaoud, Chaima $u Institute of Parasitology, Biology Centre, Czech Academy of Sciences, České Budějovice, Czechia
- 700 1_
- $a M'ghirbi, Youmna $u Institut Pasteur de Tunis, LR19IPTX, Service d'Entomologie Médicale, Université de Tunis El Manar, Tunis, Tunisia
- 700 1_
- $a Faria, Fernanda $u Innovation and Development Laboratory, Innovation and Development Center, Instituto Butantan, São Paulo, Brazil
- 700 1_
- $a Chmelar, Jindr Ich $u Department of Medical Biology, Faculty of Science, University of South Bohemia in České Budějovice, České Budějovice, Czechia
- 700 1_
- $a Kotsyfakis, Michail $u Institute of Parasitology, Biology Centre, Czech Academy of Sciences, České Budějovice, Czechia $u Department of Medical Biology, Faculty of Science, University of South Bohemia in České Budějovice, České Budějovice, Czechia
- 773 0_
- $w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 11, č. - (2020), s. 583845
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33072132 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101725 $b ABA008
- 999 __
- $a ok $b bmc $g 1690822 $s 1140554
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 11 $c - $d 583845 $e 20200923 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
- LZP __
- $a Pubmed-20210728